We are differentiated by our unwavering commitment to global expansion and patient centered innovation while maintaining an adaptive cultural mindset.

Manufacturing scalability.

We consistently make smart investments across our global facilities to expand their capacity and improve systems, enhancing efficiency and automation.

2 Capacity
for an Ortho-K facility in Virginia, USA
2 Footprint
for mark’ennovy, increasing capacity fourfold

Market Expansion.

Led by a team with deep clinical, regulatory and business expertise in each of our key industry segments, we are uniquely capable of helping further accelerate and globalize our winning companies.

Working directly with regulatory authorities in China and the U.S., we are currently conducting active prospective clinical studies to bring more patient centered products to the marketplace.

Centralized Capabilities.

We have centralized our global infrastructure and leadership to provide each company we acquire with necessary resources, while allowing them to maintain an independent, entrepreneurial culture. Our integration efforts are focused on key support functions, including HR, IT and Finance.

This approach fosters the ability of our companies to focus on scaling opportunities worldwide.

Patient-centered innovation.

We take a holistic approach to advancing our companies and their technologies. That means starting and ending with the patient’s needs and awareness about their unique condition.

After identifying the full range of needs for a disease state, we then leverage our know-how across our organization – from material science to product design – to help foster innovative specialty solutions for each one. Our goal is to ensure every patient, no matter how complex their condition, has access to personalized eye care.

Recently, we created a holistic solution for myopia management that includes a variety of lens modalities for both daytime use and overnight wear.

“

What we’re doing today is positioning us to become a global leader in managing common, complex conditions and capturing the entire specialty contact lens market.

Linda Chang, Chief Financial Officer
About Linda expand
Linda Chang, Chief Financial Officer
About Linda expand

Linda Chang is a financial expert with a well-balanced financial background that enhances any business environment. Ms. Chang’s executive experience, largely as a Chief Financial Officer, encompassed organizations of all sizes. Her experience includes numerous merger & acquisition activities, preparing for a public offering, financial restructurings, implementation of control environments and relocation/consolidation of business operations. In addition to managing finance and accounting operations, she has managed information technology, administrative, contracts, human resources, and legal functions.

Ms. Chang is currently the Chief Financial Officer of Euclid Vision Group. Prior to her role at Euclid, Ms. Chang served as Chief Financial Officer and Chief Operating Office of Science and Medicine Group. She was the Chief Financial Officer and Treasurer of Osiris Therapeutics, the Senior Vice President, Chief Financial Officer of Therabron Therapeutics, the Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of Pharmathene and the Senior Finance Director of Human Genome Sciences, Inc.